Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Mirdametinib and Vinblastine for Newly Diagnosed or Previously Untreated Patients With Pediatric Low-grade Glioma and Activation of the MAPK Pathway

NCT06666348 is registered in ClinicalTrials.gov with St. Justine's Hospital as lead sponsor.

NCT NCT06666348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06666348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Mirdametinib and Vinblastine for Newly Diagnosed or Previously Untreated Patients With Pediatric Low-grade Glioma and Activation of the MAPK Pathway
Lead sponsor
St. Justine's Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 12, 2026
Completion date
April 30, 2033
Enrollment
50 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric low-grade glioma